Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 vs Toripalimab in Neoadjuvant Treatment of Locally Advanced NSCLC
NCT07863999Phase 3Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2026
- Primary completion
- Dec 2033
- Countries
- 1
01
Overview
Phase 3, randomised trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Pathologic Complete Response Rate at 30 months. Started May 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07863999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863999.